Floodgates Open For Tecfidera Rivals
Cipla, Dr Reddy’s And Camber Confirm Launches In US
Following Mylan’s initial launch of a generic rival to Biogen’s $3.8bn Tecfidera brand, other generics companies are now following the firm into the US dimethyl fumarate market.
